 Several presentations at ASCO covering the VV21-21 CAR-TESAL construct covering the Janssen, the J&J Cartitude Trial, and there was some new constructs also trying to improve on the efficacy of CAR-TESALs. So I think the first one and that's the largest clinical trial that has ever been performed in multiple myeloma with CAR-TESALs was the CARMA trial and in the CARMA trial, 140 patients with very advanced multiple myeloma were treated. So a high proportion of patients, triple refractory and more than one quarter of the patients, even PENTA refractory, which means that the patient is refractory not only to Revlimid and Belkei Portesimib, but also to Andy C.D.38, Andy Badis, Dara Tumomar, or Issa Tuxima, and to Car-Filsumib and Pomalidumib. So really a very extremely intensively pre-treated patient population with multiple myeloma cells that were kind of refractory to everything that was available for patients in most of our countries. And in spite of this, at the highest dose level, the response rate was more than 80%, nearly 40% actually achieved a complete remission and at the highest dose level, we now see a progression-free survival of more than 12 months and in patients that are achieving a complete remission and also being MRD negative, the progression-free survival at least very intensively pre-treated patients was more than 20 months. So I think it's in the beginning, I thought maybe we should cure every patient with CAR-T cells, but I think if we consider these extremely heavily pre-treated patients and the other options that we have, this is an exceptional treatment outcome. So I think CAR-T cells are really offering a completely new treatment modality for patients with multiple myeloma. The other point which I want to mention is also the safety. Most of the patients develop some cytokine release syndrome that's mainly fever. Some of these patients need some fluids to stabilize the circulation. But I think with all this, in the vast majority of patients, it was extremely well tolerated. On the other hand, there is a small proportion of patients that really develop a more severe cytokine release syndrome where we need vasopressors to stabilize the blood pressure or that they really develop some neurotoxicity, but this was only about 6%, so rather limited, especially when compared to patients with lymphoma or ALL in which CAR-T cell therapy is much more cumbersome and has a much higher percentage of severe cytokine release syndrome and neurotoxicity. So in summary, it's a fairly safe treatment. It requires 14 days of inpatient therapy and it's extremely effective in patients with very advanced multiple myeloma. The CAR-T2 trial is another CAR construct. It has two binding domains to BCMA and the follow-ins who are the short but the response rate in a heavily pretreated patient cohort is even higher. So we have 100% overall response rate with more than 66% complete remissions and with a short follow-up of about 11 months, most nearly, I think only four or five patients actually had a procreational relapse. So again, an extremely effective treatment and I think it really confirms that CAR-T cell therapy is making a difference in the future for treatment of multiple myeloma. Then we have some new constructs. One is the ALRA cell or the other one is a construct, the BB217 which is a specific, both are specific T cell construct or they have a specific T cell composition. So they have more T cells with a longer persistence because persistence of the CAR-T cells in most of the trials up to now is an issue. So after about one year, most of the patients have lost their CAR-T cells. So now a lot of strategies like this ALRA cell or with the BB21217 are trying to create a CAR-T cell product that can persist for a longer time period in a patient and thereby to increase the efficacy or another strategy also developed by the BMS and Juno is the gamma secretase inhibitor in addition to the CAR-T cells. So they can actually increase the expression of BCMA on the myeloma cells and thereby also increase the efficacy. So CAR-T cell therapy is really becoming reality and we all believe that in the beginning of next year, maybe even at the end of this year, we already have with the ID cell one of these CAR-T cell products available for patients outside of clinical trials. I think the issue of course is like with all the CAR-T cells is the price. It's a very expensive treatment. Apart from this, I think the tolerability, the safety of the product is quite good when compared especially to the other CAR-T cell products that are now already commercially available for patients with lymphoma and ALL. I think it's an issue that the treatment has to be restricted to certain centers that are really equipped in managing patients with CAR-T cells and also managing the side effects of CAR-T cells. I think that the novel constructs, I was mentioning the BB21-217, the over cell, also the follow-up of the Cartitude Trial which looks extremely promising, also the Juno study with the combination of the gamma secretase inhibitor with the BCMA-targeted CAR-T cells. Also, I think it's very interesting, CAR-T cell trials are targeting targets apart from BCMA like SLEMF7 plus CD38, so there will be one European study that was funded by the European Commission, the CARAMBA trial which is going to start in the next two weeks here in Würzburg but also in other European centers in which SLEMF7 CAR-T cell product is being used to treat patients with multiple myeloma. So of course at the moment it's a treatment which requires inpatient therapy for at least 14 days. So this is clearly an issue. Also the product has to be generated, it takes some time and we have to bridge the patient between the look of the leukocytes, the leukophoresis and the CAR-T cell reinfusion. So in some of these trials it can take five to six weeks until we get the CAR-T cell therapy back and it's often not easy to bridge the patient. So this is clearly an issue and for every health care system the price of the CAR-T cell products are clearly an issue and we have to see how much the different national health services in Europe are going to cover the CAR-T cell therapy. But it has happened in lymphoma and ALL in most of the European countries so I'm very optimistic that we'll soon see at least the BCMA CAR-T cell especially the BB2121 IDESOL product to be available for patients with multiple myeloma. I think what we have to learn is that it's a new technology and it's improving enormously so what we see now is the first or second generation CAR-T cell product but we see more and more new developments coming so I think we can all be very optimistic about the further development of CAR-T cells also for our myeloma patients.